At RedMedEd, increasing clinician competence and improving patient care is the name of the game.

With a track record of excellence in CME and a wide range of innovative gamification and interactive learning designs, the RedMedEd team delivers initiatives that are fresh, rigorous, engaging, and memorable.

When CME is done well, clinicians learn and patients win.

Cytokines, Janus Kinase Inhibitors, and Small-Molecule Therapies, Oh My!: New Inroads Into Rheumatoid Arthritis Management

Although the introduction of biologic agents has transformed treatment paradigms for rheumatoid arthritis (RA), a considerable proportion of patients do not respond sufficiently to these therapies. A potential new therapeutic alternative for these patients is small-molecule inhibitors, which offer targeted inhibition of intracellular pathways that can be achieved via oral administration. To real...
University of Chicago Pritzker School of Medicine and RedMedEd

Ensuring Transfusion Safety for Multiple Myeloma Patients Receiving Anti-CD38 Monoclonal Antibody Therapy

Monoclonal antibody (mAb) therapy has shown promise for patients with relapsed multiple myeloma (MM), a discovery leading to the FDA’s 2015 approval of two mAbs, elotuzumab (anti-SLAMF7) and daratumumab (anti-CD38), for use in relapsed MM patients. This marks the first approved use of mAbs in MM treatment—and brings new challenges for clinicians who manage patients with MM. It was recentl...
University of Cincinnati, RedMedEd

Multiple Myeloma Patient Management: Embracing New Advancements, Overcoming New Challenges

The multiple myeloma clinical landscape has evolved significantly, with not only 10 new drugs but also new staging standards (ie, the R-ISS), imaging techniques, and maintenance therapy options added in the last 12 years. To help hematologist-oncologists keep pace with these advancements and to illustrate their optimal use in practice, this Virtual Practice reviews two multiple myeloma patient c...
Multiple Myeloma Research Foundation, RedMedEd, and Penn State College of Medicine

RME Hot Seat – Severe Asthma: Clinical Phenotypes and the Emerging Age of Personalized Therapy

Patients with severe treatment-resistant asthma—estimated to account for 4%–10% of all asthma cases—are characterized by persistent symptoms, compromised lung function, and a significantly increased frequency and severity of high-risk outcomes. These patients are typically insensitive to corticosteroid treatment, except at very high doses—and are thus at greater risk for several serious ...
RedMedEd and Rutgers Biomedical and Health Sciences

Scale, Bail, or Fail – The CDK4/6 Inhibition Edition

Preclinical and clinical findings suggest that CDK4/6 inhibition may confer therapeutic benefits in numerous tumor types and improve outcomes in patients with mantle cell lymphoma, liposarcoma, melanoma, and non–small cell lung cancer. Additionally, studies of CDK4/6 inhibition of cancers of the prostate, lung, skin, and central nervous system are currently under way. In the format of an en...
University of Cincinnati and RedMedEd

Severe Asthma Virtual Practice: Clinical Phenotypes and the Emerging Age of Personalized Therapy

Up to 10% of asthma patients have severe, treatment-resistant disease that is associated with a greater incidence of emergency room visits, hospitalizations, and other high-risk outcomes. Often, these patients are only responsive to corticosteroid treatment when it is given at very high doses, which over time can lead to type 2 diabetes, osteoporosis, dyspeptic disorders, and cataracts. The FDA...
RedMedEd and Rutgers Biomedical and Health Sciences

YouTube Google+ Pinterest Twitter LinkedIn Facebook SlideShare
RXinsider,, and our advertising partners do not endorse and do not verify the accuracy of the content in the activities presented on the website or within our mobile apps. RXinsider,, and our advertising partners are not responsible for errors, omissions, or misrepresentations contained within activities presented on the CESearchEngine website or or within our mobile apps. For complete details, please read the Terms of Service. Site Map.